480 related articles for article (PubMed ID: 19585548)
21. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
[TBL] [Abstract][Full Text] [Related]
22. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
23. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
24. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
25. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
[TBL] [Abstract][Full Text] [Related]
26. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review.
Othman MO; Dunkelberg J; Roy PK
Arab J Gastroenterol; 2012 Sep; 13(3):103-10. PubMed ID: 23122450
[TBL] [Abstract][Full Text] [Related]
27. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
[TBL] [Abstract][Full Text] [Related]
28. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Ma H; Zeng M; Han Y; Yan H; Tang H; Sheng J; Hu H; Cheng L; Xie Q; Zhu Y; Chen G; Gao Z; Xie W; Wang J; Wu S; Wang G; Miao X; Fu X; Duan L; Xu J; Wei L; Shi G; Chen C; Chen M; Ning Q; Yao C; Jia J
Medicine (Baltimore); 2016 Nov; 95(47):e5391. PubMed ID: 27893675
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
Gilger MA; Gann ME; Opekun AR; Gleason WA
J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
[TBL] [Abstract][Full Text] [Related]
31. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
[TBL] [Abstract][Full Text] [Related]
33. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
34. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
36. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
37. [Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid].
Schönfeld J; Zotz R; Mahl M; Beste M; Breuer N; Goebell H
Z Gastroenterol; 1996 Feb; 34(2):123-7. PubMed ID: 8659187
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
